Sueta Daisuke, Koibuchi Nobutaka, Hasegawa Yu, Toyama Kensuke, Uekawa Ken, Katayama Tetsuji, Ma MingJie, Nakagawa Takashi, Waki Hidefumi, Maeda Masanobu, Ogawa Hisao, Kim-Mitsuyama Shokei
Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
Department of Physiology, Wakayama Medical University School of Medicine, Wakayama, Japan.
Atherosclerosis. 2014 Sep;236(1):101-7. doi: 10.1016/j.atherosclerosis.2014.06.016. Epub 2014 Jun 26.
Elderly hypertensive patients are characterized by blood pressure (BP) variability, impaired autonomic function, and vascular endothelial dysfunction and stiffness. However, the mechanisms causing these conditions are unclear. The present study examined the effect of angiotensin receptor blockers (ARBs) on aged spontaneously hypertensive rats (SHR).
We surgically implanted telemetry devices in SHR and WKY at the age of 15 weeks (Young) and 80 weeks (Aged). Aged SHR were orally administered either olmesartan or valsartan once daily at 19:00 h (at the beginning of the dark period (active phase)) for 4 weeks to examine the effects on BP variability, impaired autonomic function, and vascular senescence.
Aging and hypertension in SHR additively caused the following: increased low frequency (LF) power of systolic BP, a decreased spontaneous baroreceptor reflex gain (sBRG), increased BP variability, increased urinary norepinephrine excretion, increased vascular senescence-related beta-galactosidase positive cells and oxidative stress. Treatment with olmesartan or valsartan significantly ameliorated these changes in aged SHR. However, olmesartan ameliorated these changes in aged SHR better than valsartan. The reductions in BP caused by olmesartan in aged SHR were sustained longer than reductions by valsartan. This result indicates longer-lasting inhibition of the AT1 receptor by olmesartan than by valsartan.
ARBs ameliorated autonomic dysfunction, BP variability, and vascular senescence in aged SHR. Olmesartan ameliorated the aging-related disorders better than valsartan and was associated with longer-lasting AT1 receptor inhibition by olmesartan. Thus, the magnitude of improvement of these aging-related abnormalities differs for ARBs.
老年高血压患者具有血压(BP)变异性、自主神经功能受损以及血管内皮功能障碍和僵硬等特征。然而,导致这些情况的机制尚不清楚。本研究探讨了血管紧张素受体阻滞剂(ARB)对老年自发性高血压大鼠(SHR)的影响。
我们在15周龄(年轻)和80周龄(老年)的SHR和WKY大鼠体内手术植入遥测装置。从19:00(黑暗期(活跃期)开始)每天口服给予老年SHR奥美沙坦或缬沙坦,持续4周,以研究其对血压变异性、自主神经功能受损和血管衰老的影响。
SHR的衰老和高血压叠加导致以下情况:收缩压低频(LF)功率增加、自发性压力感受器反射增益(sBRG)降低、血压变异性增加、尿去甲肾上腺素排泄增加、血管衰老相关β-半乳糖苷酶阳性细胞增加以及氧化应激增加。奥美沙坦或缬沙坦治疗可显著改善老年SHR的这些变化。然而,奥美沙坦比缬沙坦更能改善老年SHR的这些变化。老年SHR中奥美沙坦引起的血压降低持续时间比缬沙坦更长。这一结果表明奥美沙坦对AT1受体的抑制作用比缬沙坦更持久。
ARB可改善老年SHR的自主神经功能障碍、血压变异性和血管衰老。奥美沙坦比缬沙坦更能改善与衰老相关的疾病,且与奥美沙坦对AT1受体的持久抑制有关。因此,不同ARB对这些与衰老相关异常的改善程度有所不同。